Stock Market Top Gainers and Fridays Biggest Movers

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  21 Feb 2025
 

Nuburu $BURU led the pack with an impressive 43.93% surge. The laser technology company announced plans to expand into defense and cybersecurity through strategic acquisitions. The Centennial, Colorado-based firm intends to secure a technology license to bolster its defense capabilities, acquire a majority stake in a defense-tech company specializing in military vehicles and security systems, and gain control of a SaaS startup focused on cybersecurity. These acquisitions will occur in two phases, signaling long-term growth potential in high-demand sectors. The market's enthusiastic response highlights investor confidence in Nuburu’s diversification into defense and cybersecurity, industries expected to see sustained growth amid rising global security concerns. The momentum in BURU’s stock reflects optimism that these acquisitions could significantly enhance revenue streams and market positioning.

Celsius Holdings $CELH soared 27.77% following the release of strong fourth-quarter earnings and the announcement of a $1.8 billion acquisition of Alani Nu, a rival energy drink brand. The acquisition is expected to expand Celsius’ product offerings and consumer base, reinforcing its position in the competitive energy beverage market. The company's record full-year revenue reassured investors about its growth trajectory, driving the stock higher. Analysts have taken note of Celsius’ strategic move to capitalize on the growing demand for healthier energy drinks, and the market reaction suggests confidence that the Alani Nu acquisition will accelerate revenue growth and strengthen its competitive edge. The trend indicates strong bullish sentiment, with investors betting that Celsius can sustain its momentum as it integrates the new brand into its portfolio.

Acelyrin $SLRN climbed 19.82% after confirming an unsolicited acquisition offer from Concentra Biosciences. The proposal includes a cash offer of $3.00 per share plus a contingent value right entitling shareholders to 80% of the net proceeds from any future out-licensing or sale of Acelyrin’s development programs or intellectual property. The offer reflects confidence in Acelyrin’s late-stage immunology pipeline and its potential to deliver transformative medicines. The market’s positive response suggests investors are optimistic that the acquisition could unlock significant value, especially given the contingent value right's potential upside. With immunology being a high-growth sector, Acelyrin’s stock is likely to remain in focus as investors assess the likelihood of the acquisition closing and the possible long-term benefits.

Innodata $INOD posted a 13.47% gain, driven by bullish analyst ratings and upward revisions in price targets. Four analysts recently evaluated the AI-driven data engineering company, with the average 12-month price target rising to $60.50—a 22.22% increase from the previous average of $49.50. Notably, Maxim Group raised its target from $54.00 to $75.00, and BWS Financial boosted its target from $45.00 to $74.00, both assigning a “Buy” rating. Wedbush also initiated coverage with an “Outperform” rating and a $48.00 target. These upgrades highlight growing confidence in Innodata’s ability to capitalize on the accelerating demand for AI and data analytics solutions. The stock’s upward momentum suggests investors expect continued growth as the company benefits from its expanding role in enabling digital transformation across industries.